| |
Efficiency & productivity in biologics manufacturing is a longstanding goal, as increasingly complex molecules transform approaches to drug development. Process intensification, with advanced techniques & high productivity platforms, accelerates this pace of innovation. Read white paper. .png)
|
|
Today's Big NewsJul 25, 2023 |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
| By Kevin Dunleavy In a sizable cost-cutting measure, Biogen will lay off 1,000 employees by 2025, it announced in presenting its second quarter earnings. With the company starting 2023 with 8,725 employees, that’s an 11.5% reduction of the workforce. |
|
|
|
| Philadelphia, PA |  |
|
|
By Max Bayer The IPO window is starting to crack open and Affini-T Therapeutics plans to push through in 2024, CEO Jak Knowles told Fierce Biotech. |
By Conor Hale The company also reported that a faster-flowing supply chain has allowed it to fulfill more customer requests, as patients continue to return for elective procedures. |
By Fraiser Kansteiner Enrique Conterno has resigned from the FibroGen CEO post for “personal reasons,” the company said Tuesday. As FibroGen looks for a permanent successor, the company’s chief commercial officier Thane Wettig will don the mantle of interim chief executive officer. To support Wettig, Conterno plans to stick around as a special advisor to the CEO during a transition period. |
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about tools for interacting with medical images, guiding readers through labeling workflows, and streamlining adjudication and data standardization. Real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows will be discussed. Register now. 
|
|
By Andrea Park Seven is turning out to be a less-than-lucky number for Danaher: For the second quarter in a row, the conglomerate has reported a year-over-year drop in revenues of around 7%. |
By Nick Paul Taylor The squeeze on SQZ Biotechnologies is getting tighter. After 12 months of value destruction, the biotech reported that Roche has dropped its option on a solid tumor program—and that it is assessing strategic alternatives to partner “all its clinical and preclinical assets across all disease areas and indications.” |
By Zoey Becker Xdemvy eyedrops are the first treatment for Demodex blepharitis, an eyelid disease caused by Demodex mites. In trials, the drug reduced mites and the presence of the ectoparasites' waste and eggs. |
By Conor Hale Vantive, with its home and hospital dialysis systems, is expected to make its debut as a publicly traded company by July 2024 at the latest. |
By Angus Liu Just as the calls for a business separation grow louder at Bayer, the company’s weedkiller performance is bolstering the argument with dramatically declining sales. |
By Andrea Park A new day has dawned for people with multiple sclerosis, thanks to the launch of a new app that aims to help them better understand the disease and, in doing so, improve their care. |
By Max Bayer Biogen’s significant internal cost-cutting efforts have not deterred an aggressive hunt for deals, but CEO Chris Viehbacher doesn’t want infatuation to cloud necessary judgment. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
|
Thursday, August 17, 2023 | 11am ET / 8am PT In this webinar, we will discuss the challenges and opportunities for WGBS in an era of cost-effective sequencing: Optimizing protocols and reagents for consistent and reliable results, establishing community standards to ensure WGBS library quality, and more. Register now.
|
|
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
